Breaking Down BioNTech: 16 Analysts Share Their Views

Nov 6, 2024 · 16 analysts have expressed a variety of opinions on BioNTech (NASDAQ:BNTX) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following …

CouponFollow Extension

$127.53
OFF

What Analysts Are Saying About BioNTech Stock - Nasdaq

3 weeks from now

Nov 8, 2024 · Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, a high estimate of $150.00, and a low …

nasdaq.com

$145.43
OFF

Cracking The Code: Understanding Analyst Reviews For BioNTech

3 weeks from now

Mar 21, 2024 · Analysts have set 12-month price targets for BioNTech, revealing an average target of $145.43, a high estimate of $171.00, and a low estimate of $100.00.

businessinsider.com

49%
OFF

Time To Worry? Analysts Are Downgrading Their BioNTech SE …

3 weeks from now

After the downgrade, the consensus from BioNTech's 16 analysts is for revenues of €4.7b in 2023, which would reflect a substantial 49% decline in sales compared to the last year of …

yahoo.com

$800
OFF

Latest News For BioNTech (NASDAQ:BNTX) Stock - Benzinga

3 weeks from now

Jan 14, 2025 · Critical Insights From BioNTech Analyst Ratings: What You Need To Know ... BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition. ...

benzinga.com

$184.56
OFF

Breaking Down Tenet Healthcare: 16 Analysts Share Their Views

3 weeks from now

Jan 7, 2025 · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $184.56, with a high estimate of $217.00 and a low estimate of $140.00.

nasdaq.com

$110.92
OFF

Evaluating BioNTech: Insights From 12 Financial Analysts

3 weeks from now

Jun 26, 2024 · Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $110.92, along with a high estimate of $122.00 and a low …

businessinsider.com

$395.25
OFF

Breaking Down Accenture: 16 Analysts Share Their Views

3 weeks from now

Dec 19, 2024 · The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $395.25, a high estimate of $429.00, and a low estimate of $360.00.

nasdaq.com

51%
OFF

BioNTech Fair Value Analysis Yields 51% Return In Six Months

3 weeks from now

2 days ago · The Fair Value analysis identified a potential upside of 37.4%, supported by BioNTech's strong financial health score and promising oncology pipeline. In the following …

investing.com

73%
OFF

Breaking Down Biogen: 18 Analysts Share Their Views

3 weeks from now

Jan 28, 2025 · Breaking Down Biogen: 18 Analysts Share Their Views. Benzinga News 28/01 17:00. ... a high estimate of $300.00, and a low estimate of $138.00. A 16.73% drop is evident …

sahmcapital.com

73%
OFF

Breaking Down Biogen: 18 Analysts Share Their Views - Nasdaq

3 weeks from now

Jan 28, 2025 · Breaking Down Biogen: 18 Analysts Share Their Views ... A 16.73% drop is evident in the current average compared to the previous average price target of $257.94. ...

nasdaq.com

FAQs about Breaking Down BioNTech: 16 Analysts Share Their Views Coupon?

How do analysts evaluate biontech's market performance?

Price Targets: Analysts navigate through adjustments in price targets, providing estimates for BioNTech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations. For valuable insights into BioNTech's market performance, consider these analyst evaluations alongside crucial financial indicators. ...

How do analysts react to biontech's latest developments?

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioNTech. This information provides a snapshot of how analysts perceive the current state of the company. ...

What do analyst ratings mean for biontech?

These ratings convey expectations for the relative performance of BioNTech compared to the broader market. Price Targets: Analysts navigate through adjustments in price targets, providing estimates for BioNTech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations. ...

How do analysts evaluate biontech (BNT) stock?

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BioNTech compared to the broader market. Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BioNTech's stock. ...

Are analysts downgrading biontech se (bntx) forecasts?

Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook Market forces rained on the parade of BioNTech SE ( NASDAQ:BNTX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business. ...

Should you buy biontech se (bntx – research report)?

BioNTech SE ( BNTX – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $113.00 price target. ...